

CORRESPONDENCE OPEN



CHRONIC LYMPHOCYTIC LEUKEMIA

Updates of the ERIC recommendations on how to report the results from immunoglobulin heavy variable gene analysis in chronic lymphocytic leukemia

© The Author(s) 2024

Leukemia (2024) 38:679–680; <https://doi.org/10.1038/s41375-024-02163-4>

TO THE EDITOR:

The treatment paradigm of chronic lymphocytic leukemia (CLL) is rapidly shifting from chemoimmunotherapy (CIT) to novel targeted agents. Recent randomized studies have consistently documented the superiority of chemo-free treatment with targeted therapies over CIT in patients with CLL [1–3], rendering the latter either not recommended or a less preferred option, as also reflected in recently published international guidelines [4, 5]. On these grounds, we deem it necessary to introduce some changes to the recommendations by ERIC, the European Research Initiative on CLL [6], on how to report results from immunoglo-

bulin heavy variable (IGHV) gene analysis in CLL in order to reflect the recent advancements in CLL therapy.

More particularly, the aim of this update is to emphasize on the need to inform clinicians about the existing knowledge (or lack thereof) on the predictive value of IGHV gene somatic hypermutation (SHM) status in the era of targeted agents (Table 1 and Supplemental Material). Specifically, ERIC proposes that the laboratory report for patients found by sequencing analysis to carry unmutated IGHV genes should also mention that these patients display shorter progression-free survival when treated with fixed-duration treatment, such as venetoclax plus obinutuzumab compared to IGHV-mutated cases [7]. Finally, the laboratory reports of patients identified as belonging to CLL stereotyped subset #2 should state that this is a prognostically adverse patient group regardless the SHM status [8, 9] while also acknowledging the lack of evidence about the predictive value of subset #2 in the era of targeted therapies.

Table 1. Proposed changes in the interpretation section of the previous examples.

Example of the IGHV report	Interpretation
IGHV-unmutated	Following the 98% germline identity cut-off which is used for discriminating CLL cases into the IGHV-mutated or IGHV-unmutated category, this case belongs to the IGHV-unmutated category which is generally associated with adverse prognosis and poor response to chemoimmunotherapy and a shorter progression-free survival when treated with fixed-duration treatments that include venetoclax plus an anti-CD20 antibody compared to IGHV-mutated cases [7].
Subset #2	Following the 98% germline identity cut-off which is used for discriminating CLL cases into the IGHV-mutated or IGHV-unmutated category, this case belongs to the IGHV-mutated category. However, this particular rearrangement belongs to stereotyped subset #2 which is associated with adverse prognosis and poor response to chemoimmunotherapy regardless of the somatic hypermutation status [8, 9]. The predictive value of subset #2 for patients treated with targeted therapies is currently unknown.

Thomas Chatzikonstantinou ¹, Andreas Agathangelidis^{1,2}, Anastasia Chatzidimitriou^{1,3}, Cristina Tresoldi ⁴, Zadie Davis ⁵, Véronique Giudicelli ⁶, Sofia Kossida ⁶, Chrysoula Belessi⁷, Richard Rosenquist ^{3,8}, Paolo Ghia ^{9✉}, Anton W. Langerak ¹⁰, Frédéric Davi¹¹, Kostas Stamatopoulos^{1,3} and ERIC, the European Research Initiative on CLL*

¹Institute of Applied Biosciences, Centre for Research and Technology Hellas, Thessaloniki, Greece. ²Department of Biology, School of Science, National and Kapodistrian University of Athens, Athens, Greece. ³Department of Molecular Medicine and Surgery, Karolinska Institutet, Stockholm, Sweden. ⁴Division of Immunology, Transplantation and Infectious Diseases, IRCCS Ospedale San Raffaele, Milan, Italy. ⁵Department of Molecular Pathology, University Hospitals Dorset, Bournemouth, UK. ⁶International ImMunoGeneTics Information System (IMGT), Institut de Génétique Humaine (IGH), Centre National de la Recherche Scientifique (CNRS), Université de Montpellier, Montpellier, France. ⁷Hematology Department, Nikea General Hospital, Pireaus, Greece. ⁸Clinical Genetics, Karolinska University Hospital, Stockholm, Sweden. ⁹Division of Experimental Oncology, Università Vita-Salute San Raffaele and IRCCS Ospedale San Raffaele, Milan, Italy. ¹⁰Department of Immunology, Laboratory Medical Immunology, Erasmus MC, Rotterdam, The Netherlands. ¹¹Department of Hematology, APHP, HôpitalPitié-Salpêtrière and Sorbonne University, Paris, France. *A list of authors and their affiliations appears at the end of the paper.

✉email: ghia.paolo@hsr.it

Received: 21 December 2023 Revised: 17 January 2024 Accepted: 19 January 2024
Published online: 16 February 2024









REFERENCES

1. Al-Sawaf O, Zhang C, Tandon M, Sinha A, Fink AM, Robrecht S, et al. Venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab for previously untreated chronic lymphocytic leukaemia (CLL14): Follow-up results from a multicentre, open-label, randomised, phase 3 trial. *Lancet Oncol.* 2020;21:1188–1200.
2. Eichhorst B, Niemann CU, Kater AP, Furstenaus M, von Tresckow J, Zhang C, et al. First-line venetoclax combinations in Chronic Lymphocytic Leukemia. *N Engl J Med.* 2023;388:1739–54.
3. Shanafelt TD, Wang XV, Hanson CA, Paietta EM, O'Brien S, Barrientos J, et al. Long-term outcomes for ibrutinib-rituximab and chemoimmunotherapy in CLL: updated results of the E1912 trial. *Blood.* 2022;140:112–20.
4. National Comprehensive Cancer Network (NCCN). NCCN Clinical Practice Guidelines in Oncology. Chronic Lymphocytic Leukemia/ Small Lymphocytic Lymphoma Version 1.2024. 2023 Nov 3; National Comprehensive Cancer Network. Available from: https://www.nccn.org/professionals/physician_gls/pdf/cll.pdf.
5. Wendtner CMA-SO, Binder M, Dreger P, Eichhorst B, Gregor M, et al. Onkopedia guidelines on CLL. Jan 2023. Available from: <https://www.onkopedia.com/de/onkopedia/guidelines/chronische-lymphatische-leukaemie-cll/@guideline/html/index.html>.
6. Agathangelidis A, Chatzidimitriou A, Chatzikonstantinou T, Tresoldi C, Davis Z, Giudicelli V, et al. Immunoglobulin gene sequence analysis in chronic lymphocytic leukemia: The 2022 update of the recommendations by ERIC, the European Research Initiative on CLL. *Leukemia.* 2022;36:1961–8.
7. Al-Sawaf O, Zhang C, Jin HY, Robrecht S, Choi Y, Balasubramanian S, et al. Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia. *Nat Commun.* 2023;14:2147.
8. Baliakas P, Agathangelidis A, Hadzidimitriou A, Sutton LA, Minga E, Tsanousa A, et al. Not all IGHV3-21 chronic lymphocytic leukemias are equal: prognostic considerations. *Blood.* 2015;125:856–9.
9. Jaramillo S, Agathangelidis A, Schneider C, Bahlo J, Robrecht S, Tausch E, et al. Prognostic impact of prevalent chronic lymphocytic leukemia stereotyped subsets: Analysis within prospective clinical trials of the German CLL Study Group (GCLLSG). *Haematologica.* 2020;105:2598–607.

AUTHOR CONTRIBUTIONS

All authors contributed to the article and approved the submitted version. T.C. wrote the manuscript, A.A., A.C., C.T., Z.D., V.G., S.K., C.B., R.R., A.W.L., and F.D. edited the text and gave final approval. P.G. and K.S. wrote the manuscript, edited the text, and gave final approval.

ERIC, THE EUROPEAN RESEARCH INITIATIVE ON CLL

Thomas Chatzikonstantinou ¹, Andreas Agathangelidis^{1,2}, Anastasia Chatzidimitriou^{1,3}, Cristina Tresoldi ⁴, Zadie Davis ⁵, Véronique Giudicelli ⁶, Sofia Kossida ⁶, Chrysoula Belessi⁷, Richard Rosenquist ^{3,8}, Paolo Ghia ⁹✉, Anton W. Langerak ¹⁰, Frédéric Davi¹¹ and Kostas Stamatopoulos^{1,3}

COMPETING INTERESTS

TC received honoraria from AbbVie, RR has received honoraria from AbbVie, AstraZeneca, Janssen, Illumina, and Roche. PG: received honoraria from AbbVie, AstraZeneca, BeiGene, BMS, Galapagos, Janssen, Loxo@LillyOncology, MSD, Roche; research funds from AbbVie, AstraZeneca, BMS; Janssen, AWL has received research support from Janssen, Gilead and Roche, FD has received honoraria from Janssen and Gilead, KS received honoraria from Janssen, Lilly, AstraZeneca; and research support from Janssen, Abbvie, AstraZeneca.

ADDITIONAL INFORMATION

Supplementary information The online version contains supplementary material available at <https://doi.org/10.1038/s41375-024-02163-4>.

Correspondence and requests for materials should be addressed to Paolo Ghia.

Reprints and permission information is available at <http://www.nature.com/reprints>

Publisher's note Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.



Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if changes were made. The images or other third party material in this article are included in the article's Creative Commons licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this licence, visit <http://creativecommons.org/licenses/by/4.0/>.

© The Author(s) 2024